2011 AHA guidelines recommend the use of<unk><unk>  aspirin (Level of Evidence: B) and P2Y12 receptor inhibitor (clopidogrel, prasugrel and ticagrelor) (Level of Evidence: A) to<unk>  PCI in patients with ACS. Few randomised trials have been conducted showing comparison of clopidogrel with aspirin and other P2Y12 inhibitors (prasugrel and ticagrelor) in terms of clinical benefit and risk of bleeding when given in patients undergoing PCI. However, there is limited data comparing new P2Y12 receptor inhibitors (prasugrel and ticagrelor) for downstream and upstream<unk>  in patients undergoing PCI with non ST elevation MI in terms of clinical benefit and adverse effects. Hence, a new large scale randomised open label trial called DUBIUS is in process in Italy comparing two new P2Y12 inhibitors prasugrel and ticagrelor for pretreatment in patients with non ST elevation MI undergoing PCI.
Antiplatelet therapy to support PCI
PCI in the angulated or tortuous lesion
PCI in the patient at risk of bleeding
Stent thrombosis introduction
Intervention in left main coronary artery disease
PCI in the patient with severely depressed ventricular function
PCI in the long lesion
PCI in the patient with in stent restenosis